Figure 3.

Antitumor activity of selpercatinib against metastatic brain lesions in patients with RET fusion-positive NSCLC. Waterfall plot showing the percent change in brain target lesion size in the CNS population according to IRC evaluation. Waterfall plots only show patients with measurable target lesions. Among the eight patients with brain metastases at baseline, three had nonmeasurable disease.

CNS, central nervous system; IRC, independent review committee; NSCLC, non-small-cell lung cancer.